GSK (LON:GSK) Earns Buy Rating from Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Financial Group in a report released on Tuesday, Digital Look reports. They presently have a GBX 2,500 price target on the stock. Jefferies Financial Group’s price target indicates a potential upside of 33.83% from the company’s previous close.

Other analysts also recently issued reports about the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 1,975 price target on shares of GSK in a research report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Tuesday, September 29th. Finally, Berenberg Bank lifted their price target on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday, September 15th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, GSK currently has an average rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Price Performance

Shares of LON GSK traded down GBX 0.50 during trading on Tuesday, reaching GBX 1,868. The company had a trading volume of 9,241,153 shares, compared to its average volume of 12,467,660. GSK has a 52 week low of GBX 1,592 and a 52 week high of GBX 2,282. The business’s 50 day moving average price is GBX 1,845.12 and its 200-day moving average price is GBX 1,922.33. The stock has a market cap of £74.85 billion, a PE ratio of 15.86, a PEG ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Analysts expect that GSK will post 175.98 earnings per share for the current year.

Insider Activity

In related news, insider Anne Beal acquired 637 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were purchased at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds purchased 1,500 shares of the stock in a transaction on Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Insiders have bought a total of 2,151 shares of company stock worth $6,021,921 over the last 90 days. 0.20% of the stock is owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.